Matinas BioPharma Holdings, Inc.
MTNB
$0.9129
$0.0131.45%
AMEX
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -97.53% | -35.17% | -32.05% | -5.28% | -13.20% |
Gross Profit | 97.53% | 35.17% | 32.05% | 5.28% | -19.90% |
SG&A Expenses | -24.23% | -25.20% | -24.55% | -5.08% | -9.44% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -67.03% | -31.41% | -28.58% | -5.20% | -11.67% |
Operating Income | 67.03% | 31.41% | 28.58% | 5.20% | -5.66% |
Income Before Tax | 71.57% | -60.20% | 29.40% | 5.63% | -5.64% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 71.57% | -58.69% | 29.40% | 5.63% | -5.64% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 71.57% | -58.69% | 29.40% | 5.63% | -5.64% |
EBIT | 67.03% | 31.41% | 28.58% | 5.20% | -5.66% |
EBITDA | 66.82% | 31.82% | 28.92% | 5.18% | -5.79% |
EPS Basic | 75.70% | -35.51% | 39.10% | 17.77% | -5.60% |
Normalized Basic EPS | 71.38% | 34.40% | 39.10% | 17.77% | -5.59% |
EPS Diluted | 75.70% | -35.51% | 39.10% | 17.77% | -5.60% |
Normalized Diluted EPS | 71.38% | 34.40% | 39.10% | 17.77% | -5.59% |
Average Basic Shares Outstanding | 17.02% | 17.11% | 15.94% | 14.77% | 0.04% |
Average Diluted Shares Outstanding | 17.02% | 17.11% | 15.94% | 14.77% | 0.04% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |